Study on Serum Zinc and Selenium Levels in Epileptic Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study was carried out with the purpose of evaluating zinc and selenium levels in serum of epileptic patients and compare with normal individuals.
| Condition |
|---|
|
Generalized Epileptic |
| Study Type: | Observational [Patient Registry] |
| Study Design: | Observational Model: Case Control Time Perspective: Cross-Sectional |
| Target Follow-Up Duration: | 1 Week |
| Official Title: | Arak University of Medical Sciences , Ministry of Health and Education,I.R.Iran |
- Study on Serum Zinc and Selenium Levels in Epileptic Patients [ Time Frame: 5 months ] [ Designated as safety issue: Yes ]decrement in serum zinc and selenium level
- Comparison between the selenium levels by gender in two groups [ Time Frame: 5 months ] [ Designated as safety issue: Yes ]
Biospecimen Retention: None Retained
Serum were analysis for zinc and selenium
| Enrollment: | 40 |
| Study Start Date: | November 2011 |
| Study Completion Date: | May 2012 |
| Primary Completion Date: | March 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Zinc level (micro gram per deciliter)
In all cases
|
|
Selenium level (micro gram per deciliter)
In all cases
|
| Zinc level in male (micro gram per deciliter) |
| Selenium level in male (micro gram per deciliter) |
| Zinc level in Female (micro gram per decilitre) |
| Selenium level in Female (micro gram per decilitre) |
Detailed Description:
Forty patients aged 18 to 50 years visiting Vali-Asr hospital in Arak, I.R. Iran, who were diagnosed with generalized form of epilepsy by a neurologist for the first time were recruited as cases. The control group (n=40) was selected from healthy individuals, in whom no disease was diagnosed until this study, and were matched to the case group by age, sex, and economical status.
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
all generalized and single epileptic patiants which were identify for fist time
Inclusion Criteria:
New generalized and single epileptic cases patients who accept and sign the approval form of ethical committee non smoker, no trauma, no use of selenium supplement, no use of zinc supplement, no use of vitamin A supplement, no use of vitamin D supplement, no Weight loss, no Diarrhea, no addiction, no alcohol consumption, no use of certain medications,
Exclusion Criteria:
presence of above criteria as well as, generalized and single epileptic cases under treatment
Contacts and Locations| Iran, Islamic Republic of | |
| Vali-Asr Hospital | |
| Arak, Central province, Iran, Islamic Republic of | |
| Principal Investigator: | Heidar N Farahani, PhD | Department of Biochemistry,Arak medical sciences university |
More Information
No publications provided
| Responsible Party: | Dr. Farahani Heidar, faculity of medicine, department of biochemistry, Arak University of Medical Sciences |
| ClinicalTrials.gov Identifier: | NCT01764516 History of Changes |
| Other Study ID Numbers: | f110@1958, f110@19588, f110@19588, f110@19588 |
| Study First Received: | January 5, 2013 |
| Last Updated: | January 5, 2013 |
| Health Authority: | Iran: Ethics Committee Iran: Ministry of Health |
Keywords provided by Arak University of Medical Sciences:
|
zinc selenium serum epilepsy antioxidants |
Additional relevant MeSH terms:
|
Epilepsy Brain Diseases Central Nervous System Diseases Nervous System Diseases Selenium Trace Elements Micronutrients |
Growth Substances Physiological Effects of Drugs Pharmacologic Actions Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents |
ClinicalTrials.gov processed this record on May 16, 2013